US Civilian Smallpox Preparedness and Response Program, 2003
- PMID: 18284355
- DOI: 10.1086/524751
US Civilian Smallpox Preparedness and Response Program, 2003
Abstract
Variola virus, the cause of smallpox disease, has been deemed a possible bioterrorism agent. Since November 2001, federal, state, and local public health partners implemented activities to prepare for a possible smallpox outbreak. The Centers for Disease Control and Prevention (CDC) produced and delivered training and educational materials for smallpox preparedness in many formats, developed detailed smallpox vaccine information statements about vaccine contraindications and vaccination site care, and established mechanisms to monitor and respond to adverse events after smallpox vaccination. The last included enhancements to the Vaccine Adverse Event Reporting System, a pregnancy registry for inadvertently vaccinated pregnant women, and a Clinician Telephone Information Line to collect reports about adverse events. The civilian responder vaccination program was conducted with rigorous safety procedures, and few historically recognized adverse events were observed. However, myocarditis and/or pericarditis was newly recognized as an adverse event caused by the New York City Board of Health vaccinia vaccine strain. This smallpox preparedness program put into place a number of measures to advance the United States' readiness for a smallpox outbreak that have assisted in preparedness for other threats.
Similar articles
-
Economics of cardiac adverse events after smallpox vaccination: lessons from the 2003 US Vaccination Program.Clin Infect Dis. 2008 Mar 15;46 Suppl 3:S168-78. doi: 10.1086/524380. Clin Infect Dis. 2008. PMID: 18284356
-
Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January-October 2003.Clin Infect Dis. 2008 Mar 15;46 Suppl 3:S242-50. doi: 10.1086/524747. Clin Infect Dis. 2008. PMID: 18284365
-
Monitoring the safety of a smallpox vaccination program in the United States: report of the joint Smallpox Vaccine Safety Working Group of the advisory committee on immunization practices and the Armed Forces Epidemiological Board.Clin Infect Dis. 2008 Mar 15;46 Suppl 3:S258-70. doi: 10.1086/524749. Clin Infect Dis. 2008. PMID: 18284367
-
The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program.Vaccine. 2005 Mar 18;23(17-18):2078-81. doi: 10.1016/j.vaccine.2005.01.012. Vaccine. 2005. PMID: 15755574 Review.
-
Smallpox vaccine: the reality, the risk.RN. 2003 Jul;66(7):52-8; quiz 60. RN. 2003. PMID: 12900999 Review. No abstract available.
Cited by
-
Smallpox vaccines for biodefense: need and feasibility.Expert Rev Vaccines. 2008 Oct;7(8):1225-37. doi: 10.1586/14760584.7.8.1225. Expert Rev Vaccines. 2008. PMID: 18844596 Free PMC article. Review.
-
Assessing risk in chronic kidney disease: a methodological review.Nat Rev Nephrol. 2013 Jan;9(1):18-25. doi: 10.1038/nrneph.2012.248. Epub 2012 Nov 20. Nat Rev Nephrol. 2013. PMID: 23165299 Review.
-
Secondary and tertiary transmission of vaccinia virus from US military service member.Emerg Infect Dis. 2011 Apr;17(4):718-21. doi: 10.3201/eid1704.101316. Emerg Infect Dis. 2011. PMID: 21470470 Free PMC article.
-
An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications.Expert Rev Anti Infect Ther. 2021 Mar;19(3):331-344. doi: 10.1080/14787210.2020.1819791. Epub 2020 Sep 15. Expert Rev Anti Infect Ther. 2021. PMID: 32882158 Free PMC article. Review.
-
Statistical approach to estimate vaccinia-specific neutralizing antibody titers using a high-throughput assay.Clin Vaccine Immunol. 2009 Aug;16(8):1105-12. doi: 10.1128/CVI.00109-09. Epub 2009 Jun 17. Clin Vaccine Immunol. 2009. PMID: 19535540 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical